StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the stock.
Separately, Cantor Fitzgerald reaffirmed an overweight rating and set a $2.50 target price on shares of VolitionRx in a report on Thursday, May 16th.
Check Out Our Latest Report on VolitionRx
VolitionRx Stock Performance
VolitionRx (NYSE:VNRX – Get Free Report) last announced its earnings results on Monday, May 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. Sell-side analysts forecast that VolitionRx will post -0.31 EPS for the current year.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Further Reading
- Five stocks we like better than VolitionRx
- 3 Stocks to Consider Buying in October
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- What is the Euro STOXX 50 Index?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What Are the U.K. Market Holidays? How to Invest and Trade
- MarketBeat Week in Review – 7/29 – 8/2
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.